# OnCo record acticca-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/acticca-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "acticca-1", "NCT02170090" ;
  schema:name "ACTICCA-1"@en ;
  schema:description "ACTICCA-1 asks whether six months of gemcitabine and cisplatin after surgery beats the current standard for bile duct and gallbladder cancer. It recruited 789 patients across eight countries including 24 UK hospitals, has a separate gallbladder cohort, and finished recruiting; results are awaited."@en ;
  schema:url <https://onco.cc/trials/acticca-1/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02170090>, <https://doi.org/10.1186/s12885-015-1498-0> ;
  onco:status "active" ;
  onco:phase "3" ;
  onco:related <https://onco.cc/trials/bilcap/> ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:institutions <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026/> .